Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Down 5.98%
As of Thursday, September 24, Compass Therapeutics, Inc.’s CMPX share price has dipped by 5.98%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Down 5.65%
As of Wednesday, September 23, Compass Therapeutics, Inc.’s CMPX share price has dipped by 5.65%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Down 32.42%
As of Tuesday, September 22, Compass Therapeutics, Inc.’s CMPX share price has dipped by 32.42%, which has investors questioning if this is right time to buy.Michael Rose
Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Down 27.47%
As of Tuesday, September 22, Compass Therapeutics, Inc.’s CMPX share price has dipped by 27.47%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Down 5.26%
As of Monday, September 21, Compass Therapeutics, Inc.’s CMPX share price has dipped by 5.26%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | CMPX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $203.5 | $257.9 | 28% |
|
| Shares Out (Mil) | 186.8 | 54.3 | 75% |
|
| Institutional Ownership | 93.1% | 92.9% | 62% |
|
| Float (Mil) | 132.4 | 41.4 | 66% |
|
| Beta | 0.85 | 0.95 | 51% |
|
| Avg Daily Volume (000s) | 6,363 | 674 | 93% |
|
| Price Change (52-week) |
(67.6%) | 51.5% | 11% |
|
| Growth | CMPX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (17.7%) | (10.1%) | 22% |
|
| EPS (5yr) | 15.1% | 15.8% | 57 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (16.1%) | (15.6%) | 45% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 10 | |
| Current EPS | ($0.126) | ($0.485) | ($0.538) | |
| Month Ago EPS | ($0.128) | ($0.491) | ($0.535) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.106) | ($0.436) | ($0.463) | |
| Year/Year Chg | (6.7%) | 14.9% | 28.0% | |
| Financials | CMPX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($73) | ($43) | 13% |
|
| EPS (TTM) | ($0.404) | ($1.600) | 29% |
|
| Operating Cash Flow (TTM) (Mil) | ($56) | ($32) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $13 | $2 | 58% |
|
| Long-Term Debt (Q1) (Mil) | $8 | $4 | 27% |
|
| Enterprise Value (Q1) (Mil) | $172 | $174 | 25% |
|
| Valuation | CMPX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.23 | 2.51 | 31% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CMPX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (47.9%) | (47.7%) | 12% |
|
| ROE | (56.7%) | (54.9%) | 14% |
|
| Liabilities to Assets | 12.7% | 29.1% | 8% |
|
| F-Score | 2 | 3 | 7% |
|
Compass Therapeutics, Inc. did not pass any screens on 9/25/2026.
